Welcome to our dedicated page for Evolus SEC filings (Ticker: EOLS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Evolus, Inc. (EOLS) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, with AI-powered tools to help interpret the details. Evolus is a Nasdaq-listed performance beauty company focused on aesthetic injectables, and its filings provide formal insight into financial performance, governance, and key events affecting its Jeuveau neurotoxin and Evolysse hyaluronic acid (HA) gel portfolio.
Investors can use this page to access current and historical 10-K and 10-Q reports, which describe Evolus’ business, risk factors, and financial statements, including revenue contributions from Jeuveau and Evolysse products and discussion of non-GAAP operating metrics. Form 8-K filings, such as those announcing quarterly results or executive appointments, document material events like financial updates, leadership changes, and significant clinical or commercial milestones.
The page also surfaces Form 4 insider transaction reports, where applicable, which disclose purchases, sales, or grants of Evolus common stock by directors and officers. These filings allow users to track how insiders’ equity holdings change over time in connection with inducement grants, stock option awards, and restricted stock units described in company announcements.
Stock Titan’s AI features summarize lengthy filings into plain-language highlights, explaining how items such as non-GAAP operating income, restructuring costs, or contingent royalty obligations appear in Evolus’ disclosures. Real-time updates from EDGAR ensure that new 8-Ks, 10-Qs, and 10-Ks are added as soon as they are filed, while AI-generated overviews help users quickly identify sections related to revenue trends, operating expenses, executive compensation agreements, and governance provisions. This combination of raw documents and AI analysis helps investors, analysts, and other stakeholders understand the regulatory record behind EOLS stock and the company’s performance beauty strategy.
Evolus, Inc. Chief Financial Officer Tatjana Mitchell reported equity awards on Form 4. She acquired 121,489 performance restricted stock units, 177,471 stock options, and 121,489 shares of common stock at a grant price of $0.00 per share, all held directly.
The restricted stock units vest in four equal annual installments starting on February 17, 2026, with potential acceleration upon certain terminations or a change in control. The performance-based units can deliver up to 200% of the granted amount based on financial metrics and relative total shareholder return over a three-year period ending December 31, 2028. The stock options also vest in four equal annual installments beginning on February 17, 2026, subject to continued service and similar acceleration conditions.
White Albert G III reported acquisition or exercise transactions in this Form 4 filing.
Evolus, Inc. director Albert G. White III received an equity award of 45,559 shares of common stock in the form of restricted stock units (RSUs) on February 17, 2026. The award was granted at no cash cost per share and is a stock-based compensation grant, not an open-market purchase.
Each RSU represents a contingent right to receive one Evolus common share and will vest in full on “the one year anniversary of February 17, 2026,” if he remains in continuous service, with potential accelerated vesting upon certain changes of control. Following this grant, his reported direct holdings total 95,937 shares of common stock.
MOATAZEDI DAVID reported acquisition or exercise transactions in this Form 4 filing.
Evolus, Inc. director and officer David Moatazedi reported equity awards on February 17, 2026. He was granted 626,424 performance-based restricted stock units, where each unit can deliver up to 200% of a target share amount based on financial metrics and relative total shareholder return over a three-year period ending December 31, 2028. He also received 313,212 time-based restricted stock units and 457,541 stock options, each vesting in four equal annual installments starting on February 17, 2026, subject to continued service and potential acceleration in certain circumstances.
Malik Vikram reported acquisition or exercise transactions in this Form 4 filing.
Evolus, Inc. director Vikram Malik reported an equity award of 45,559 shares of common stock in the form of restricted stock units (RSUs). Each RSU represents the right to receive one share of Evolus common stock for no cash payment.
The RSUs will vest in full on the one year anniversary of February 17, 2026, as long as Malik remains in continuous service, with accelerated vesting possible in certain change-of-control or similar events. After this grant, Malik beneficially owns 321,109 shares of Evolus common stock.
Avelar Rui reported acquisition or exercise transactions in this Form 4 filing.
Evolus, Inc. reported that company officer Rui Avelar received new equity awards on February 17, 2026. Grants included 94,913 performance-based restricted stock units, 94,913 time-based restricted stock units payable in common stock, and stock options for 138,649 shares at no cost on grant.
The time-based RSUs and options vest in four equal annual installments starting February 17, 2026, subject to continued service and possible acceleration in certain circumstances. The performance-based units can deliver up to 200% of the granted PSUs based on financial metrics and relative total shareholder return over a three-year period ending December 31, 2028.
GILL DAVID N reported acquisition or exercise transactions in this Form 4 filing.
Evolus, Inc. director David N. Gill received a grant of 45,559 restricted stock units (RSUs) of common stock. The award was made at no cash cost per share and will vest in full on the one-year anniversary of February 17, 2026, if he remains in continuous service. Following this grant, Gill directly holds 86,887 shares or share-equivalent RSUs.
Evolus, Inc. received an updated ownership report from Caligan Partners LP and David Johnson showing they no longer beneficially own any of its common stock. The filing states each reporting person has 0 shares with sole or shared voting and dispositive power, representing 0.0% of the common stock class as of the reported date. The reporters also certify the securities were acquired and held in the ordinary course of business and not for the purpose of changing or influencing control of Evolus.
Tang Capital Management and related entities reported beneficial ownership of Evolus, Inc. common stock totaling 1,245,692 shares, representing 1.92% of the outstanding class. These shares are held with shared, not sole, voting and dispositive power across several Tang-affiliated funds and entities.
The ownership is spread among Tang Capital Partners, Tang Capital Partners International, Tang Capital Partners III, and Tang Capital Partners IV, with Kevin Tang sharing voting and investment authority. The filing notes that the securities are not held for the purpose of changing or influencing control of Evolus.
Timothy P. Lynch reports beneficial ownership of 6,425,726 shares of Evolus, Inc. common stock, representing 9.9% of the class. This includes 4,705,009 shares over which he has sole voting and dispositive power and 1,720,717 shares with shared voting and dispositive power.
The ownership percentage is based on 64,819,784 shares of Evolus common stock outstanding as of October 31, 2025, as reported by the company. Lynch states that the securities were not acquired and are not held for the purpose of changing or influencing control of Evolus.
Evolus, Inc. filed a current report to disclose that it has issued a press release with preliminary, unaudited net revenue and other operational and financial data for the quarter and year ended December 31, 2025. The press release, dated January 9, 2026, is included as an exhibit to the report.
The company states that this information, including the exhibit, is being furnished rather than filed, which limits the legal exposure associated with these preliminary figures and keeps them separate from formal Securities Act and Exchange Act filings unless specifically incorporated by reference.